Last updated: May 26, 2026
Vasopressin is supplied through a mix of branded/marketed finished-dose manufacturers (where applicable) and suppliers of vasopressin active pharmaceutical ingredient (API) and related injection products for hospitals and wholesalers. Availability and labeling vary by country and by concentration (typical strengths include 0.5 units/mL and 20 units/mL for injection, plus ophthalmic-grade variants in some markets).
The supplier landscape falls into three practical buckets: (1) API manufacturers supplying injectable-grade vasopressin, (2) finished-dose injectable manufacturers that package under their own label, and (3) distributors/wholesalers that source from API and finished-dose channels.
Because vasopressin is an older, widely used peptide drug and procurement is driven by tendering and sourcing qualification, the key business need is mapping who can supply injectable-grade vasopressin at required concentrations, with consistent GMP documentation, DMF/CEP/CoA capability, and country-specific regulatory status.
Which companies supply vasopressin API for injection?
Answer: Vasopressin API supply for injection typically comes from peptide-focused manufacturers and chemical/pharma ingredient manufacturers that maintain injectable-grade peptide production, controls, and QC release testing.
API supplier categories and what procurement teams verify
Procurement qualification for vasopressin API usually focuses on:
- Manufacturing site GMP status for peptide/API production
- Sterility/pyrogen strategy relevance (even if API is non-sterile, drug product must meet final specs)
- Peptide identity and purity (HPLC profile and related substances)
- Salt form and assay specification alignment to the finished-dose formulation
- Stability and retest periods for API storage and handling
- Supply continuity through peptide batch sizing and capacity planning
Common geographies for vasopressin API supply
- Europe: peptide and specialty API manufacturers with injectable-grade QA systems
- United States: API makers and peptide specialists supporting legacy injectables
- India and China: high-volume API and peptide manufacturers often active in global tender supply, subject to qualification
(A definitive “top list” of named API suppliers requires Orange Book equivalents or national product registries and DMF/CEP disclosures tied to specific marketed presentations by jurisdiction. The supplier universe is presentation- and market-dependent.)
Who manufactures vasopressin injection drug products (finished dosage forms)?
Answer: Finished vasopressin injection suppliers are usually manufacturers of hospital injectables and specialty injectables, with product labeling by strength and container type (ampoule vs vial) and with country-specific regulatory approvals.
Finished-dose formats that drive supplier selection
Procurement specs often distinguish:
- Concentration (commonly 0.5 U/mL and 20 U/mL presentations)
- Container (vial vs ampoule; glass type)
- Solvent and excipients (preservative, pH adjusters)
- Labeling language and strength expression (U vs mg equivalents depending on regulatory conventions)
- Traceability and lot release for hospital distribution
What hospitals and distributors prioritize
- Lead time under tender and emergency restocking
- Allocation policy during constrained supply
- Batch-to-batch consistency and aligned assay/purity release testing
- Documentation pack: CoA, GMP cert, stability schedule, and regulatory listing evidence
How to source vasopressin ophthalmic vs injectable suppliers (product-line split)?
Answer: Ophthalmic vasopressin preparations, where marketed, often come from different manufacturers than injectable vasopressin. Do not treat ophthalmic supply as interchangeable with injection supply.
Supplier separation by route
- Injectables: regulated to sterility, particulate control, and injectable peptide formulation specs
- Ophthalmic: sterile ophthalmic requirements plus ocular tolerability excipients
Procurement implication
Supplier qualification should be route-specific:
- Sterility assurance and container closure system validation
- Ocular vs injectable excipient acceptance criteria
- Route-specific stability data and shelf-life confirmation
What is the FDA status of vasopressin products and who is listed as applicants?
Answer: In the US, vasopressin products are regulated through the FDA drug approval and listing system. Applicant/manufacturer details depend on the specific presentation (strength, dosage form, NDC) and whether the listing is in an application type that triggers Orange Book visibility for patents (not all products will show patent listings).
Why supplier identification requires NDC-level mapping
Even when the active ingredient is the same, suppliers differ by:
- NDC (labeler code reflects manufacturer/distributor)
- strength
- dosage form
- pack configuration
For US procurement, the actionable workflow is:
- select the target strength and dosage form
- map the NDC to the FDA labeler/manufacturer
- pull the listing that reflects the regulated supply chain entity
(A concrete “who exactly supplies vasopressin X units/mL injection in the US” list cannot be produced here without NDC-specific product selection and Orange Book/FDA labeler table extraction.)
Which suppliers are most relevant for global vasopressin shortages and tenders?
Answer: In constrained supply, procurement tends to converge on manufacturers with:
- multiple qualified dosage lines
- long-running relationships with tenders
- batch capacity for peptide synthesis and sterile fill-finish
Risk factors that change the supplier list
- peptide raw material supply continuity
- sterility fill-finish capacity
- regional regulatory holds
- shipment and allocation policies
Operational procurement controls
- dual-source qualification for each target strength
- safety stock by lead time
- lot release alignment and review process
- incoming CoA verification
What documentation do vasopressin suppliers typically provide for qualification?
Answer: Suppliers of vasopressin injectable-grade product or API generally provide:
- CoA for each lot (assay, related substances, impurities, endotoxin/bioburden where relevant)
- GMP certificate for the manufacturing site
- Drug product: sterility and particulate-related documentation
- API: identity and purity, plus retest/stability protocol
- Stability summary and shelf-life statement
Quality agreements procurement teams require
- Quality Agreement (QA) between supplier and customer
- change control notification windows
- deviation/CAPA notification rules
- recall responsibilities
How does vasopressin supply differ from desmopressin supplier ecosystems?
Answer: Although vasopressin and desmopressin both target water balance pathways, their supplier ecosystems often differ because:
- they are different peptide sequences with different peptide suppliers and synthesis lines
- excipient and formulation requirements differ for each product
- regulatory filings and NDC labelers differ by country
Procurement implication
Treat the supplier list as route and product-specific. Do not infer vasopressin supply from desmopressin suppliers.
What generic entry and biosimilar issues affect vasopressin suppliers?
Answer: Vasopressin is not typically a biosimilar target. The relevant competitive dynamics are generics of vasopressin injections and supply chain substitution by NDC equivalence where allowed.
Key “entry” issue for sourcing
- product discontinuations and relabeling
- differences in strength expression
- container/pack changes that affect tender eligibility
Key Takeaways
- Vasopressin sourcing splits into API suppliers, finished-dose injection manufacturers, and distributors; the active ingredient supply list is not the same as finished-dose labeler lists.
- Supplier qualification should be presentation-specific by strength, dosage form, container, and route.
- In procurement and qualification, the practical differentiators are GMP site readiness, sterile fill-finish capability, and documentation/lot release consistency.
- In the US, identifying “who supplies” requires mapping to the exact NDC and the FDA listing for the labeled manufacturer.
FAQs
- What strength specifications should be verified when sourcing vasopressin injection?
- Can vasopressin API suppliers be used to source finished sterile injectables directly?
- How do I qualify a vasopressin supplier for hospital tender use?
- Does ophthalmic vasopressin supply qualify as injectable supply?
- Why do vasopressin and desmopressin suppliers differ even though both are vasopressin analogs?
References
- FDA Drug Establishments and Drug Product listings (FDA.gov).
- National drug product registries and medicine databases for vasopressin injection labelers by country (e.g., EMA product database where applicable).
